TCL Archive ODAC Nixes Sanofi’s VTE Drug in 14-1 Vote, Setting High Bar For Adjunctive Therapies June 22, 2012
TCL Archive NCI Considering Adoption Of NIGMS Guidelines To Limit Growth Of Renewals, Ensure New Grants November 30, 1990
TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive In Brief; NCAB To Hear Report On Human Cancer Virus, Mayo Projects, Proposed FDA Regulations February 28, 1975
TCL Archive NCAB Committee Approves Staff Plan For New Comprehensive Cancer Center Grant Mechanism April 29, 1988
